| Target Price | $714.00 |
| Price | $447.76 |
| Potential | 59.46% |
| Number of Estimates | 22 |
| 22 Analysts have issued a price target Axon Enterprise Inc 2027 . The average Axon Enterprise Inc target price is $714.00. This is 59.46% higher than the current stock price. The highest price target is $871.50 94.64% , the lowest is $446.73 0.23% . | |
| A rating was issued by 28 analysts: 25 Analysts recommend Axon Enterprise Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Axon Enterprise Inc stock has an average upside potential 2027 of 59.46% . Most analysts recommend the Axon Enterprise Inc stock at Purchase. |
24 Analysts have issued a sales forecast Axon Enterprise Inc 2026 . The average Axon Enterprise Inc sales estimate is
This results in the following potential growth metrics:
22 Analysts have issued an Axon Enterprise Inc EBITDA forecast 2026. The average Axon Enterprise Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Axon Enterprise Inc Analysts have issued a net profit forecast 2026. The average Axon Enterprise Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
25 Analysts have issued a Axon Enterprise Inc forecast for earnings per share. The average Axon Enterprise Inc EPS is
This results in the following potential growth metrics and future valuations:
Axon Enterprise Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Argus Research |
Buy
➜
Buy
|
Unchanged | Sep 03 2026 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Aug 06 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 06 2026 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 06 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Aug 06 2026 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Jul 13 2026 |
| Needham |
Buy
➜
Buy
|
Unchanged | Jul 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Argus Research:
Buy
➜
Buy
|
Sep 03 2026 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Aug 06 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 06 2026 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 06 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Aug 06 2026 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Jul 13 2026 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Jul 06 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


